503 Backend fetch failed

Error 503 Backend fetch failed

Backend fetch failed

Guru Meditation:

XID: 59047969


Varnish cache server

Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

DECIPHERA PHARMACEUTICALS, INC.

(DCPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Business Summary
Logo Deciphera Pharmaceuticals, Inc.
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing, and delivering medicines to patients for the treatment of cancer. The Company developed a switch-control kinase inhibitor platform in kinase biology to execute its strategy to develop a broad portfolio of medicines. The Company has one approved drug, QINLOCK, which is a switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). In addition, the Company is developing three clinical-stage drug candidates, which includes Vimseltinib (DCC-3014) - colony stimulating factor 1 receptor (CSF1R) Kinase Inhibition for Tenosynovial Giant Cell Tumor (TGCT), Rebastinib - TEK tyrosine kinase (TIE2) Kinase Inhibition for advanced or Metastatic Solid Tumors, and DCC-3116 - ULK Kinase Inhibition for Mutant RAS/RAF Cancers.

Number of employees : 280 people.
Sales per Business
20202021Delta
Switch Control Kinase Inhibitor Platform42.09100%96.15100% +128.45%
USD in Million
Sales per region
2021
United States81.4884.7%
Global8.769.1%
Rest of World5.916.1%
USD in Million
Managers
Name Title Age Since
Steven L. Hoerter President & Chief Executive Officer 50 2019
Thomas P. Kelly Chief Financial Officer, Treasurer & Executive VP 50 2019
Daniel L. Flynn, Dr. President, Chief Executive Officer & Director 67 2003
Stephen B. Ruddy, Dr. Chief Technical Officer & SVP 57 2018
Matthew L. Sherman, Dr. Chief Medical Officer & Executive Vice President 65 2019
Rodrigo Ruiz Soto, Dr. Senior Vice President-Clinical Development - 2017
Daniel C. Martin Chief Commercial Officer & SVP 46 2018
Kelley Dealhoy Chief Business Officer & Senior Vice President - 2022
Jeffrey M. Held General Counsel & Senior Vice President 52 -
Jama Pitman Vice President-Regulatory & Quality Assurance 42 2015
Members of the board
Name Title Age Since
James A. Bristol, Dr. Chairman 74 2015
Patricia L. Allen Independent Director 59 2016
Edward J. Benz, Dr. Independent Director 75 2019
John R. Martin Independent Director 60 2015
Dennis L. Walsh Independent Director 53 2015
Susan L. Kelley, Dr. Independent Director 66 2019
Ron Squarer Independent Director 54 2019
Franklin S. Friedman Independent Director 63 2019
Steven L. Hoerter President & Chief Executive Officer 50 2019
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 66,822,086 48,354,481 72.4% 0 0.0% 72.4%
Shareholders
NameEquities%
Brightstar Associates LLC 18,051,348 27.0%
Deerfield Management Co. LP 6,250,964 9.35%
Armistice Capital LLC 5,400,000 8.08%
The Vanguard Group, Inc. 4,317,927 6.46%
SSgA Funds Management, Inc. 3,930,917 5.88%
Goldman Sachs & Co. LLC (Private Banking) 3,498,396 5.24%
OrbiMed Advisors Private Equity 2,183,143 3.27%
BlackRock Fund Advisors 1,860,276 2.78%
Logos Global Management LP 1,850,000 2.77%
ArrowMark Colorado Holdings LLC 1,812,710 2.71%
Brand Portfolio
In partnership withAllbrands.markets
More brands of Deciphera Pharmaceuticals, Inc.
503 Backend fetch failed

Error 503 Backend fetch failed

Backend fetch failed

Guru Meditation:

XID: 59047977


Varnish cache server